BICC1 and cholangiocarcinoma: Moreover, our straightforward fusion generation system can potentially facilitate future efforts to preclinically interrogate FGFR2–BICC1 functions in parallel with ongoing clinical trials assessing FGFR inhibitors in fusion-positive CCA [17].